Multiple Myeloma Clinical Trial
Official title:
Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft
Verified date | November 2022 |
Source | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
Status | Completed |
Enrollment | 117 |
Est. completion date | April 2021 |
Est. primary completion date | April 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Presence of a suitable related HLA-haploidentical or -matched stem cell donor, or a 10/10 matched unrelated donor - Eligible diagnoses: myelodysplastic syndrome (MDS) with at least 1 poor-risk feature; small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with 17p deletion or with progression < 6 months after a second or greater treatment regimen; T-cell prolymphocytic leukemia (PLL) in partial response or better; interferon- or tyrosine-kinase-refractory chronic myeloid leukemia (CML), or CML in second or subsequent chronic phase; Philadelphia chromosome negative (Ph-) myeloproliferative disease, including myelofibrosis; Multiple myeloma or plasma cell leukemia in partial response or better; Hematologic malignancy in complete remission with minimal residual disease (MRD) detectable by conventional cytogenetics, FISH, flow cytometry, or molecular testing - Any previous autologous transplant must have occurred > 3 months ago - Left ventricular ejection fraction (LVEF) >= 35%, or shortening fraction > 25% - Bilirubin <= 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis) - AST and ALT <= 5 x institutional upper limit of normal - FEV1 and FVC >= 40% of predicted; if unable to perform pulmonary function testing, oxygen saturation > 92% on room air - ECOG performance status <= 2, or Karnofsky/Lansky status >= 60 Exclusion Criteria: - Pregnancy or active breastfeeding - Uncontrolled active infection - Previous allogeneic transplant - Active extramedullary leukemia or active central nervous system (CNS) malignant disease |
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Who Are Able to Stop Prophylactic Tacrolimus (D90 Cohort) | This outcome measures the feasibility of stopping prophylactic tacrolimus at Day 90. | Day 90 | |
Primary | Percentage of Participants Who Are Able to Stop Prophylactic Tacrolimus (D60 Cohort) | This outcome measures the feasibility of stopping prophylactic tacrolimus at Day 60. | Day 60 | |
Secondary | Number of Participants With Grades III-IV Acute GVHD, Days 90-180 (D90) | Number of participants who experience grade III or IV acute GVHD between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable. | Between Day 90 and Day 180 | |
Secondary | Number of Participants With Grades III-IV Acute GVHD, Days 60-180 (D60) | Number of participants who experience grade III or IV acute GVHD between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable. | Between Day 60 and Day 180 | |
Secondary | Number of Participants With Chronic GVHD, Days 90-180 (D90) | Number of participants who experience chronic GVHD requiring additional immunosuppressive therapy between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable. | Between Day 90 and Day 180 | |
Secondary | Number of Participants With Chronic GVHD, Days 60-180 (D60) | Number of participants who experience chronic GVHD requiring additional immunosuppressive therapy between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable. | Between Day 60 and Day 180 | |
Secondary | Number of Participants Who Experience Graft Failure, Days 90-180 (D90) | Number of participants who experience graft failure between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable. | Between Day 90 and Day 180 | |
Secondary | Number of Participants Who Experience Graft Failure, Days 60-180 (D60) | Number of participants who experience graft failure between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable. | Between Day 60 and Day 180 | |
Secondary | Number of Participants Who Experience Disease Relapse, Days 90-180 (D90) | Number of participants who experience disease relapse between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable. | Between Day 90 and Day 180 | |
Secondary | Number of Participants Who Experience Disease Relapse, Days 60-180 (D60) | Number of participants who experience disease relapse between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable. | Between Day 60 and Day 180 | |
Secondary | Number of Participants Who Experience Non-relapse Mortality, Days 90-180 (D90) | Number of participants who die for any reason other than disease relapse between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable. | Between Day 90 and Day 180 | |
Secondary | Number of Participants Who Experience Non-relapse Mortality, Days 60-180 (D60) | Number of participants who die for any reason other than disease relapse between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable. | Between Day 60 and Day 180 | |
Secondary | Number of Participants Who Experience Grades III-IV GVHD, Day 360 (D90) | Number of participants who experience grade III or IV GVHD by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Number of Participants Who Experience Grades III-IV GVHD, Day 360 (D60) | Number of participants who experience grade III or IV GVHD by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Number of Participants With Severe Chronic GVHD, Day 360 (D90) | Number of participants who experience severe chronic GVHD requiring additional immunosuppressive therapy by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Number of Participants With Severe Chronic GVHD, Day 360 (D60) | Number of participants who experience severe chronic GVHD requiring additional immunosuppressive therapy by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Number of Participants Who Experience Graft Failure, Day 360 (D90) | Number of participants who experience graft failure by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Number of Participants Who Experience Graft Failure, Day 360 (D60) | Number of participants who experience graft failure by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Participants Who Experience Relapse, Day 360 (D90) | Number of participants who experience disease relapse by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Participants Who Experience Relapse, Day 360 (D60) | Number of participants who experience disease relapse by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Participants Who Experience Non-relapse Mortality, Day 360 (D90) | Number of participants who die for any reason other than disease relapse by Day 360. All participants are evaluable. | Day 360 | |
Secondary | Number of Participants Who Experience Non-relapse Mortality, Day 360 (D60) | Number of participants who die for any reason other than disease relapse by Day 360. All participants are evaluable. | Day 360 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |